Clinical trials: Attention Deficit Disorder (ADD)
Attention Deficit Hyperactivity Disorder (ADHD)
Crossover Study to Evaluate the Efficacy of AR11 in Pediatric Patients With ADHD in a Laboratory Classroom Setting
This is a dose-optimized, randomized, double-blind, placebo-controlled crossover study in approximately 100 pediatric patients (aged 6 to 12 years) with ADHD.
- Trial name
- NCT01986062
- Testing
- AR11
- Where
- 7 sites in United States
- Volunteers
- 97 people
- Sponsor
- Arbor Pharmaceuticals, Inc.
Insomnia, Attention Deficit Hyperactivity Disorder
Long Term Safety Study of Study Drug (Eszopiclone) in Children and Adolescents With ADHD -Associated Insomnia
A multicenter study to evaluate the safety of eszopiclone in children (6 11 years of age, inclusive) and adolescents (12 17 years of age, inclusive) with attention deficit/hyperactivity disorder (ADHD) associated insomnia.
- Trial name
- NCT00857220
- Testing
- eszopiclone
- Where
- 89 sites in United States
- Volunteers
- 304 people
- Sponsor
- Sumitomo Pharma America, Inc.
Attention Deficit Hyperactivity Disorder
Training Attentional Awareness and Control in ADHD
The purpose of this study is to evaluate the effects of different types of cognitive training on attention in adults with Attention Deficit Hyperactivity Disorder (ADHD) using mobile software on personal mobile devices.
- Trial name
- SAC-I (NCT02489279)
- Testing
- Sustained Attention Control (SAC) Method, Scrabble
- Where
- United States
- Volunteers
- 107 people
- Sponsor
- Think Now Incorporated
Attention Deficit Hyperactivity Disorder
Atomoxetine to Treat Korean Children and Adolescents With Attention-Deficit/Hyperactivity Disorder (ADHD)
The purpose of this study is to provide information regarding the relative effectiveness of three different atomoxetine doses in the treatment of Korean children and adolescents with Attention-Deficit/Hyperactivity Disorder (ADHD)
- Trial name
- NCT00568685
- Testing
- Atomoxetine Hydrochloride
- Where
- 3 sites in South Korea
- Volunteers
- 153 people
- Sponsor
- Eli Lilly and Company
Attention Deficit/Hyperactivity Disorder
A Trial of Centanafadine Efficacy and Safety in Children With Attention-deficit/ Hyperactivity Disorder (ADHD)
This trial will be conducted to evaluate the efficacy of centanafadine once daily (QD) extended release (XR) versus placebo in the treatment of child subjects (4 to 12 years, inclusive) with ADHD.
- Trial name
- NCT05428033
- Testing
- centanafadine capsule
- Where
- United States
- Volunteers
- 574 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Attention Deficit Hyperactivity Disorder
A Bioequivalence (BE) Study in Healthy Subjects
To demonstrate the bioequivalence of 12.5 milliliters (mL) of atomoxetine oral solution (4 milligrams per milliliter [mg/mL]) compared with 2 capsules of atomoxetine (25 mg per capsule) in healthy adult male Japanese subjects.
- Trial name
- NCT01177943
- Testing
- Atomoxetine
- Where
- Japan
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Adult Attention Deficit Hyperactivity Disorder
Researching the Effectiveness of Attexis, a Digital Health Application for Adults With Attention Deficit Hyperactivity Disorder
In this randomized controlled clinical trial, 326 patients with ADHD will be investigated regarding the effectiveness of a digital therapeutic for improved ADHD symptomatology, the unguided online intervention attexis.
- Trial name
- READ-ADHD (NCT06221930)
- Testing
- attexis
- Where
- Germany
- Volunteers
- 337 people
- Sponsor
- Gaia AG
Attention Deficit Hyperactivity Disorder
Dyanavel® XR Extended-Release Oral Suspension in the Treatment of Children With ADHD: A Laboratory School Study
This study was conducted to assess the efficacy and safety of DYANAVEL XR (amphetamine extended-release oral suspension, CII) for the treatment of symptoms of attention-deficit/hyperactivity disorder (ADHD) in children aged 6-12…
- Trial name
- NCT03088267
- Testing
- amphetamine extended-release oral suspension, 2.5 mg/mL
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Tris Pharma, Inc.
Attention Deficit/Hyperactivity Disorder
Efficacy and Safety Study of Methylphenidate Hydrochloride Extended Release in Adults With Childhood-onset Attention Deficit/Hyperactivity Disorder (ADHD)
This study will evaluate efficacy and safety of methylphenidate hydrochloride extended release compared to placebo in adult patients with childhood-onset attention deficit/hyperactivity disorder (ADHD).
- Trial name
- NCT01259492
- Testing
- Ritalin LA 20 mg, Ritalin LA 30 mg
- Where
- 68 sites in United States, Belgium and 7 more
- Volunteers
- 725 people
- Sponsor
- Novartis Pharmaceuticals
ADHD, Anxiety
P3b Short-term Study of CTN in Patients With ADHD and Comorbid Anxiety
Primary: To evaluate the efficacy of CTN in adults ages with ADHD and comorbid anxiety (AISRS) Key Secondary: To assess the efficacy of CTN in adults ages with ADHD and comorbid anxiety
- Conditions
- ADHD, Anxiety, Generalized Anxiety, Social Anxiety Disorder
- Trial name
- NCT06973577
- Testing
- Centanafadine
- Where
- 47 sites in United States, Puerto Rico
- Volunteers
- 315 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
ADHD
Safety and Efficacy Study of Dexmethylphenidate in Children With ADHD
The purpose of this study is to compare the safety and efficacy of two doses of dexmethylphenidate to two doses of an approved, long-acting, marketed medication for ADHD (MPH) and placebo in children ages 6-12 diagnosed with ADHD.
- Trial name
- NCT00141063
- Testing
- Focalin XR
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- Novartis
Attention Deficit Hyperactivity Disorder
An Effectiveness and Safety Study of CONCERTA* vs. Immediate Release Methylphenidate (IR MPH) in Attention Deficit Hyperactivity Disorder Children
The purpose of this study is to determine the effectiveness and safety of OROS*methylphenidate/CONCERTA* vs. immediate release methylphenidate as a treatment for ADHD specifically for those children who have behavioural…
- Trial name
- NCT00304681
- Testing
- OROS*-Methylphenidate
- Volunteers
- 147 people
- Sponsor
- Janssen-Ortho Inc., Canada
Attention Deficit Hyperactivity Disorder
ADZENYS XR-ODT™ in Children (4 to <6 Years) Diagnosed With Attention-deficit/Hyperactivity Disorder
This is a randomized, double-blind, flexible dose-titration, placebo-controlled, parallel-group study designed to evaluate the efficacy, safety, and tolerability of ADZENYS XR-ODT compared to placebo in children with ADHD.
- Trial name
- NCT07169162
- Testing
- ADZENYS XR-ODT
- Where
- United States
- Sponsor
- Aytu BioPharma, Inc.
Attention Deficit Disorder With Hyperactivity
Effectiveness of Lobeline in Treating Symptoms of ADHD in Adult Patients
The study will evaluate the effectiveness of the nonstimulant medication lobeline in improving symptoms of attention deficit hyperactivity disorder in adults.
- Trial name
- NCT00664703
- Testing
- Lobeline sulfate, Methylphenidate HCl
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Yaupon Therapeutics
Attention-deficit/Hyperactivity Disorder
Effectiveness of Vyvanse Compared to Concerta in Adolescents With Attention-deficit/Hyperactivity Disorder
The purpose of this study is to determine effectiveness of Vyvanse compared to Concerta in adolescents with Attention-deficit/Hyperactivity Disorder (ADHD).
- Trial name
- NCT01552902
- Testing
- Lisdexamfetamine dimesylate, Methylphenidate Hydrochloride
- Where
- 95 sites in United States, Canada and 3 more
- Volunteers
- 549 people
- Sponsor
- Shire
ADHD
EndeavorOTC™ Prospective Product Registry
The EndeavorOTC product registry aims to collect real world data from EndeavorOTC users. The objectives of this registry are to describe clinical and demographic characteristics, treatment patterns, clinical and quality of life…
- Trial name
- NCT06109051
- Testing
- EndeavorOTC
- Where
- United States
- Volunteers
- 198 people
- Sponsor
- Akili Interactive Labs, Inc.
Attention Deficit Hyperactivity Disorder
Long-Term Study of Atomoxetine in Children With Attention-Deficit/Hyperactivity Disorder (AD/HD)
The study is long-term extension study to evaluate long-term safety and efficacy of Atomoxetine in Japanese pediatric patients with Attention-Deficit/Hyperactivity Disorder (AD/HD).
- Trial name
- NCT00191386
- Testing
- Atomoxetine hydrochloride
- Where
- 24 sites in Japan
- Volunteers
- 228 people
- Sponsor
- Eli Lilly and Company
Attention Deficit Hyperactivity Disorder
Efficacy and Safety of NS2359 in Adults With Attention Deficit Hyperactivity Disorder
The purpose of the study is to investigate if NS2359 is effective in the treatment of ADHD in adult patients.
- Trial name
- NCT00467428
- Testing
- NS2359
- Where
- United States
- Volunteers
- 126 people
- Sponsor
- NeuroSearch A/S
Attention Deficit Disorder With Hyperactivity
Safety, Tolerability and Efficacy of SPD503 in Treating ADHD in Children Aged 6-17
The purpose of this study is to determine the effects of SPD503 compared to placebo on tasks of sustained attention in children and adolescents aged 6-17 diagnosed with ADHD.
- Trial name
- NCT00150592
- Testing
- SPD503 (Guanfacine HCl)
- Volunteers
- 182 people
- Sponsor
- Shire
Attention Deficit Hyperactivity Disorder, Dyslexia
Treatment of ADHD With Atomoxetine in Children & Adolescents With ADHD & Comorbid Dyslexia
This study will evaluate the effect of atomoxetine in treating Attention-Deficit/Hyperactivity Disorder (ADHD) symptoms in children and adolescents with ADHD and comorbid reading disability (dyslexia)
- Trial name
- NCT00607919
- Testing
- Atomoxetine
- Where
- 16 sites in United States
- Volunteers
- 209 people
- Sponsor
- Eli Lilly and Company